1.
Cardiovascular Effects of Glucagonlike peptide–1 Agonists
by Davidson, Michael H., MD
The American journal of cardiology, 2011, Vol.108 (3), p.33B-41B
2.
Safety Considerations with Fibrate Therapy
by Davidson, Michael H., MD
The American journal of cardiology, 2007, Vol.99 (6), p.S3-S18
3.
Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-con...
by Davidson, Michael H., MD
Clinical therapeutics, 2007, Vol.29 (7), p.1354-1367
4.
Cardiovascular Risk Factors in a Patient with Diabetes Mellitus and Coronary Artery Disease: Therapeutic Approaches to Improve Outcomes: Perspectives of a Preventive Cardiologist
by Davidson, Michael H., MD
The American journal of cardiology, 2012, Vol.110 (9), p.43B-49B
5.
A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESP...
by Maki, Kevin C., PhD
Clinical therapeutics, 2013, Vol.35 (9), p.1400-1411.e3
6.
Effects of Consumption of Pomegranate Juice on Carotid Intima–Media Thickness in Men and Women at Moderate Risk for Coronary Heart Disease
by Davidson, Michael H., MD
The American journal of cardiology, 2009, Vol.104 (7), p.936-942
7.
Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines
by Davidson, Michael H., MD
The American journal of cardiology, 2008, Vol.101 (12), p.S51-S57
8.
Comparison of the Safety and Efficacy of a Combination Tablet of Niacin Extended Release and Simvastatin vs Simvastatin Monotherapy in Patients With Increased Non–HDL Cholesterol (...
by Ballantyne, Christie M., MD
The American journal of cardiology, 2008, Vol.101 (10), p.1428-1436
9.
Review of the Evidence for the Clinical Utility of Lipoprotein-Associated Phospholipase A2 as a Cardiovascular Risk Marker
by Corson, Marshall A., MD
The American journal of cardiology, 2008, Vol.101 (12), p.S41-S50
10.
Changes in Cardiovascular Risk Associated With Phentermine and Topiramate Extended-Release in Participants With Comorbidities and a Body Mass Index ≥27 kg/m2
by Davidson, Michael H., MD
The American journal of cardiology, 2013, Vol.111 (8), p.1131-1138
11.
Niacin Use and Cutaneous Flushing: Mechanisms and Strategies for Prevention
by Davidson, Michael H., MD
The American journal of cardiology, 2008, Vol.101 (8), p.S14-S19
12.
Comparison of the Lipid-Lowering Effects of Pitavastatin 4 mg Versus Pravastatin 40 mg in Adults With Primary Hyperlipidemia or Mixed (Combined) Dyslipidemia: A Phase IV, Prospecti...
by Sponseller, Craig A., MD
Clinical therapeutics, 2014, Vol.36 (8), p.1211-1222
13.
Safety and Efficacy of Ezetimibe Added on to Rosuvastatin 5 or 10 mg Versus Up-Titration of Rosuvastatin in Patients With Hypercholesterolemia (the ACTE Study)
by Bays, Harold E., MD, FACP, FACE, FNLA
The American journal of cardiology, 2011, Vol.108 (4), p.523-530
14.
High-Density Lipoprotein Metabolism: Potential Therapeutic Targets
by Davidson, Michael H., MD
The American journal of cardiology, 2007, Vol.100 (11), p.S32-S40
15.
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-wee...
by Davidson, Michael H., MD
Clinical therapeutics, 2009, Vol.31 (12), p.2824-2838
16.
Peripheral artery disease, biomarkers, and darapladib
by Berger, Jeffrey S., MD, MS
The American heart journal, 2011, Vol.161 (5), p.972-978
17.
Low High-Density Lipoprotein Cholesterol and Increased Cardiovascular Disease Risk: An Analysis of Statin Clinical Trials
by Deedwania, Prakash, MD
The American journal of cardiology, 2009, Vol.104 (10), p.3E-9E
18.
Novel Targets that Affect High-Density Lipoprotein Metabolism: The Next Frontier
by Davidson, Michael H., MD
The American journal of cardiology, 2009, Vol.104 (10), p.52E-57E
19.
Baseline Lipoprotein Lipids and Low-Density Lipoprotein Cholesterol Response to Prescription Omega-3 Acid Ethyl Ester Added to Simvastatin Therapy
by Maki, Kevin C., PhD
The American journal of cardiology, 2010, Vol.105 (10), p.1409-1412
20.
The Editor's Roundtable: The JUPITER Trial—Initial Results and Clinical Implications
by Ridker, Paul M., MD, MPH
The American journal of cardiology, 2009, Vol.103 (10), p.1417-1425
